Scientific Programme

Thursday, 10 October 2019

10.00    Registration opens

12.00 – 14.00 ESU Course: New challenges and unmet needs in basic science and histopathology to address the clinical management of renal malignancies
Chair    M. Hora, Plzen (CZ)
Faculty  A. Hartmann, Erlangen (DE); R. Leao, Coimbra (PT)

See ESUR19 website for full ESU Course programme

14.30 – 14.45 Opening
Carmen Jeronimo, Porto (PT)  Meeting Chair
Kerstin Junker, Homburg (DE)  ESUR Chair
Rodolfo Montironi, Ancona (IT)  ESUP Chair

14.45 – 16.10 Session 1
Microenvironment, metabolism and epigenetic reprogramming

14.45 – 15.10 Phenotype-independent DNA methylation changes in prostate cancer
Norman Maitland, York (GB)

15.10 – 15.30 The tumour-microenvironment as a barrier or enabler of the host immune response
Gabriel Malouf, Strasbourg (FR)

15.30 – 15.50 MicroRNA expression and activity in the prostate cancer tumour microenvironment
Shawn Lupold, Baltimore US

15.50 – 16.10 The multifunctional role of the enzyme APE1/Ref-1 in bladder cancer: Growth, cell survival and muscle invasion
Travis Jerde, Indianapolis US

16.10 - 16.40 Break

16.40 – 17.40 Session 2
Translational research in bladder dysfunction

16.40 – 17.00 RNA profiling in bladder pathologies
Katia Monastyrskaya, Berne (CH)

17.00 – 17.20 Neurotrophins and stress in bladder pain
Ana Charrua, Porto (PT)

17.20 – 17.40 Regulating axonal growth for spinal cord regeneration
Martin Schwab, Zurich (CH)
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 17.40 – 17.50 | O1 *Study on the possible interactions between FGFRL1- and AR-regulated mechanisms in prostate cancer*  
Syeda Afshan, Turku (FI) |
| 17.50 – 18.00 | O2 *Mechanisms of ETS family transcription factors that promote prostate cancer*  
Peter Hollenhorst, Bloomington (US) |
| 18.00 – 18.10 | O3 *Mitochondrial complex I gene mutations drive metabolic reprogramming in prostate cancer*  
Helmut Klocker, Innsbruck (AT) |
| 18.10 – 18.20 | O4 *Metabolic reprogramming and epigenetic landscape: an interplay to renal cell carcinoma aggressiveness promotion*  
Vera Miranda-Gonçalves, Porto (PT) |
| 18.20 – 18.30 | O5 *The adipose tissue that surrounds the prostate gland exhibits traits of hypoxic state that could contribute to its role in prostate cancer progression*  
Mathieu Roumiguie, Toulouse (FR) |
Friday, 11 October 2019

08.30 – 09.40 Session 3
Epidrugs: From basics to clinical trials

08.30 – 08.50 Novel approaches to targeting the androgen receptor in CRPC
Ganesh Raj, Dallas (US)

08.50 – 09.15 Clinical trials on epigenetic therapies for urological tumours
Simon Crabb, Southampton (GB)

09.15 – 09.40 Epidrugs designing
Paola Arimondo, Paris (FR)

09.40 – 10.20 Session 4
Immuno-oncology: pre-clinical and clinical trials: Pre-clinical studies

09.40 – 10.00 Inhibition of a G9a/EZH2 network triggers an immune-mediated bladder cancer regression
Jesus Paramio, Madrid (ES)

10.00 – 10.20 Oncolytic viruses as a kick-start for immunotherapy
Gabri van der Pluijm, Leiden (NL)

10.20 – 10.50 Break

10.50 – 11.50 Session 5
Immuno-oncology: pre-clinical and clinical trials: Clinical trials

10.50 – 11.10 Mechanisms of action and resistance to BCG immunotherapy: New developments
Joost Boormans, Rotterdam (NL)

11.10 – 11.30 Immunotherapy combinations and sequences in urothelial cancer: Facts and hopes
Yohann Loriot, Villejuif (FR)

11.30 – 11.50 New combination partners of IO (eg. anti-angiogenesis) in RCC (preclinical concept and recent clinical studies)
Andreas Pircher, Innsbruck (AT)

11.50 – 12.30 Short presentations 2

11.50 – 12.00 06 Artesunate reduces cell growth and induces ferroptosis in therapy-resistant renal cell carcinoma cells
Eva Juengel, Mainz (DE)

12.00 – 12.10 07 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts
Egbert Oosterwijk, Nijmegen (NL)

12.10 – 12.20 08 Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22
Esteban Abella, San Leandro (US)

12.20 – 12.30 09 Preliminary proteomic analysis of F.F.P.E. tumor samples for predicting the response of bladder cancer patients to anti-P.D.-1/P.D.L.-1 therapy
Rafael Strogilios, Athens (GR)

12.30 – 13.30 Lunch

13.30 – 15.00 Poster session 1
Poster numbers P1 – P40
14.45 – 15.00  Break

15.00 – 16.30  Session 6  
Panel session: Local therapy in metastatic prostate cancer

15.00 – 15.15  Radiotherapy  
Noel Clarke, Manchester (GB)

15.15 – 15.30  Surgery  
Matthias Saar, Homburg (DE)

15.30 -15.45  Hormonal therapy  
Igor Tsaur, Mainz (DE)

15.45 – 16.05  Role of primary tumour for metastasis development and therapy response (including exosomes)  
Bruno Costa-Silva, Lisbon (PT)

16.05 – 16.30  Panel discussion

16.30 – 17.30  Short presentations 3

16.30 – 16.50  Role of prostate derived Ets factor in prostate cancer  
Hari Koul, Shreveport (US)

16.50 – 17.00  010  A transcription factor activity profile as a prognostic signature for androgen deprivation therapy resistance predisposition in prostate cancer patients  
Mario Cangiano, Leiden (NL)

17.00 – 17.10  011  Cytoreductive primary tumor removal slows down disease progression in an orthotopic xenograft model of prostate cancer  
Johannes Linxweiler, Homburg (DE)

17.10 – 17.20  012  Tumor-secreted exosomal miR-424: impact on prostate tumorigenesis in mouse models and patients  
Giuseppina Carbone, Bellinzona (CH)

17.20 – 17.30  013  A duplex quantitative real-time PCR assay for the detection of small non-coding RNA in urinary extracellular vesicles  
Elena Martens-Uzunova, Rotterdam (NL)
08.45 – 09.50  Session 7  
Molecular subtypes and therapeutics

08.45 – 09.10  Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal  
Scott Shepherd, London (GB)

09.10 – 09.30  Histopathological subtypes in RCC: consequences for systemic therapy  
Holger Moch, Zurich (CH)

09.30 – 09.50  Sequencing of prostate cancers identifies new cancer genes, routes of progression and  
drug targets  
David Wedge, Oxford (GB)

09.50 – 10.30  Short presentations 4

09.50 – 10.00  O14 Urothelial bladder cancer risk patterns according to tumor taxonomic subtypes  
Raquel Benitez Dorta, Madrid (ES)

10.00 – 10.10  O15 Immune infiltrate, immune checkpoints and mismatch repair proteins in testicular germ cell tumors: A role in prognosis and patient outcome  
Joao Lobo, Porto (PT)

10.10 – 10.20  O16 Immunogenomic analysis reveals that tumor aggressiveness is associated with a decreased CD8 T cell signature in an in vivo prostate cancer model  
Merle Van Gelder, Rotterdam (NL)

10.20 – 10.30  O17 The mTOR kinase directly regulates FBP1 gene expression via interaction with SWI/SNF chromatin remodeling complex in clear cell renal cell carcinoma (ccRCC)  
Elzbieta Sarnowska, Warsaw (PL)

10.30 – 11.00  Break

11.00 – 11.30  Session 8  
Data protection regulation and ethics

11.00 – 11.30  Open consent, biobanking and data protection law: Can open consent be ‘informed’ under the data protection regulation?  
Dara Hallinan, Karlsruhe (DE)

11.30 – 12.30  Short presentations 5

11.30 – 11.40  O18 A novel calcium-mediated epithelial-to-mesenchymal transition pathway controlled by lipids: an opportunity for prostate cancer adjuvant therapy  
Fanny Bery, Tours (FR)

11.40 – 11.50  O19 Biomarker exploration of extracellular vesicles in renal cell carcinoma  
Dirk Himbert, Homburg (DE)

11.50 – 12.00  O20 m6A-regulated long non-coding RNAs in prostate cancer  
Daniela Barros Silva, Porto (PT)

12.00 – 12.10  O21 Macrophage-associated changes in peri-prostatic adipose tissue; a novel local driver of prostate tumorigenesis?  
Laura Martinez Campesino, Sheffield (GB)

12.10 – 12.20  O22 Comprehensive multi-omic profiling of tumor endothelial cells of prostate tissue  
Andreas Pircher, Innsbruck (AT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12.20 – 12.30| **Q23** *Effects of systemic glucocorticoid administration on stromal and epithelial GR signalling with consequences for prostate cancer progression*  
Martin Puhr, Innsbruck (AT) |
| 12.30 – 13.30| Lunch                                                                |
| 13.30 – 15.00| **Poster session 2**  
Poster numbers P41 – P76 and LB1 – LB7 |
| 14.45 – 15.00| Break                                                                |
| 15.00 – 15.30| **Dominique Chopin Award and lecture**  
Frank Claessens, Leuven (BE) |
| 15.30 – 16.00| **ARTP Award and closing remarks**                                   |